Caroline Rynn

Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors

Philipp Holzer, Keiichi Masuya, Pascal Furet et al. · Journal of Medicinal Chemistry · 2015 · 202 citations · Full text

Dihydroisoquinolinone Derivative, Drug Target, Molecular Biology +18

A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097

Sébastien Jeay, Swann Gaulis, Stéphane Ferretti et al. · eLife · 2015 · 87 citations · Full text

In vitro assessment of colistin's antipseudomonal antimicrobial interactions with other antibiotics

Alasdair MacGowan, Caroline Rynn, Mandy Wootton et al. · Clinical Microbiology and Infection · 1999 · 51 citations · Full text

Antimicrobial Susceptibility, Health Sciences, Antibiotics +14

Discovery of Novel Allosteric EGFR L858R Inhibitors for the Treatment of Non-Small-Cell Lung Cancer as a Single Agent or in Combination with Osimertinib

U. Obst-Sander, Antônio Ricci, Bernd Kuhn et al. · Journal of Medicinal Chemistry · 2022 · 35 citations · Full text

In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitor

Andrea Vaupel, Philipp Holzer, Stéphane Ferretti et al. · Bioorganic & Medicinal Chemistry Letters · 2018 · 20 citations · Full text

Medicine, Pharmacology, Tumor Targeting +9